This week we highlighted findings from recently published cost-effectiveness studies:
- New insights into methodological derivation of thresholds used in global health:New paper reviews the underlying concepts of CEA thresholds, the derivation of the one and three times GDP per capital multipliers, and suggestions for improvement in global health research (46)
- Use of specialized oral nutritional supplements suggests considerable cost-effectiveness: Providing specialized oral nutritional supplements to prevent and combat malnutrition in older hospitalized patients was found to extend the life of patients with favorable cost-effectiveness (58)
See below for a full list of all cost-utility studies and selected reviews and editorials published January 30 – February 3, 2017. To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry. Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Aichmair A, et al. Cost-effectiveness of conservative versus surgical treatment strategies of lumbar spinal stenosis in the Swiss setting: analysis of the prospective multicenter Lumbar Stenosis Outcome Study (LSOS). Eur Spine J. 2017 Feb;26(2):501-509. PMID: 28040872.
2: Baras Shreibati J, Goldhaber-Fiebert JD, Banerjee D, Owens DK, Hlatky MA. Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure. JACC Heart Fail. 2017 Feb;5(2):110-119. PMID: 28017351.
3: Barbosa C, Cowell A, Dowd W, Landwehr J, Aldridge A, Bray J. The cost-effectiveness of brief intervention versus brief treatment of Screening, Brief Intervention and Referral to Treatment (SBIRT) in the United States. Addiction. 2017 Feb;112 Suppl 2:73-81. PMID:28074567.
4: Bardach AE, et al. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. BMC Public Health. 2017 Feb 2;17(1):152. PMID: 28148228.
5: Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, Yang Y, Li Q. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer Res Clin Oncol. 2017 Feb;143(2):361-368. PMID: 27798730.
6: Choi SE, Seligman H, Basu S. Cost Effectiveness of Subsidizing Fruit and Vegetable Purchases Through the Supplemental Nutrition Assistance Program. Am J Prev Med. 2017 Jan 30. PMID: 28153648.
7: Claxton L, Hodgson R, Taylor M, Malcolm B, Pulikottil Jacob R. Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom. Pharmacoeconomics. 2017 Feb;35(2):237-248. PMID: 27787744.
8: Connell NT, Abel GA, Connors JM. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thromb Res. 2017 Feb;150:53-58. PMID: 28039844.
9: Costa D, Peixoto Lima R. Cost-effectiveness of ambulatory blood pressure monitoring in the management of hypertension. Rev Port Cardiol. 2017 Jan 31. English, Portuguese. PMID: 28159431.
10: Coyle D. Increasing the methodological quality and relevance of cost effectiveness analysis. Thromb Res. 2017 Feb;150:121-122. PMID: 28007401.
11: Cradock AL, et al. Using cost-effectiveness analysis to prioritize policy and programmatic approaches to physical activity promotion and obesity prevention in childhood. Prev Med. 2017 Feb;95S:S17-S27. PMID: 27773710.
12: Critchlow S, Hirst M, Akehurst R, Phillips C, Philips Z, Sullivan W, Dunlop WC. A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future. J Med Econ. 2017 Feb;20(2):129-139. PMID: 27563752.
13: Cubo E, et al. Prospective study on cost-effectiveness of home-based motor assessment in Parkinson's disease. J Telemed Telecare. 2017 Feb;23(2):328-338. PMID: 27000142.
14: de Vos AS, Janssen MP, Zaaijer HL, Hogema BM. Cost-effectiveness of the screening of blood donations for hepatitis E virus in the Netherlands. Transfusion. 2017 Jan 31. PMID: 28144956.
15: Elbasha EH, Robertson MN, Nwankwo C. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. Aliment Pharmacol Ther. 2017 Feb;45(3):455-467. PMID: 27910116.
16: Elmallah RK, Chughtai M, Khlopas A, Bhowmik-Stoker M, Bozic KJ, Kurtz SM, Mont MA. Determining Cost-Effectiveness of Total Hip and Knee Arthroplasty Using the Short Form-6D Utility Measure. J Arthroplasty. 2017 Feb;32(2):351-354. PMID: 27665243.
17: Floodeen H, Hallböök O, Hagberg LA, Matthiessen P. Costs and resource use following defunctioning stoma in low anterior resection for cancer - A long-term analysis of a randomized multicenter trial. Eur J Surg Oncol. 2017 Feb;43(2):330-336. PMID: 28069399.
18: Fust K, et al. Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):39-52. PMID: 28064553.
19: Gilden DM, et al. Treatment patterns and cost-effectiveness of first line treatment of
advanced non-squamous non-small cell lung cancer in Medicare patients. J Med Econ. 2017 Feb;20(2):151-161. PMID: 27574722.
20: Grabner M, Winegar DA, Punekar RS, Quimbo RA, Cziraky MJ, Cromwell WC. Cost
Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level. Am J Cardiol. 2017 Feb 1;119(3):404-409. PMID: 27887691.
21: Groessl EJ, Sklar M, Laurent DD, Lorig K, Ganiats TG, Ho SB. Cost-Effectiveness of the Hepatitis C Self-Management Program. Health Educ Behav. 2017 Feb;44(1):113-122. PubMed PMID: 27206463.
22: Hagberg L, Hermansson L, Fredriksson C, Pettersson I. Cost-effectiveness of powered mobility devices for elderly people with disability. Disabil Rehabil Assist Technol. 2017 Feb;12(2):115-120. PMID: 25634493.
23: Hernandez I, Smith KJ, Zhang Y. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thromb Res. 2017 Feb;150:123-130. PMID: 27771008.
24: Hojjat H, et al. Cost-effectiveness of routine computed tomography in the evaluation
of idiopathic unilateral vocal fold paralysis. Laryngoscope. 2017 Feb;127(2):440-444. PMID: 27601300.
25: Huang M, Lou Y, Pellissier J, Burke T, Liu FX, Xu R, Velcheti V. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. J Med Econ. 2017 Feb;20(2):140-150. PMID: 27571538.
26: Kajihara Y, Shimoyama T, Mizuki I. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. Scand J Gastroenterol. 2017 Feb;52(2):238-241. PMID: 27806639.
27: Kearns B, Chilcott J, Whyte S, Preston L, Sadler S. Erratum to: Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation. BMC Med. 2017 Feb 3;15(1):31. PMID: 28158977.
28: Kievit W, Maurits JS, Arts EE, van Riel PL, Fransen J, Popa CD. Cost-Effectiveness of Cardiovascular Screening in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2017 Feb;69(2):175-182. PMID: 27159060.
29: Landfeldt E, Alfredsson L, Straub V, Lochmüller H, Bushby K, Lindgren P. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis. Pharmacoeconomics. 2017 Feb;35(2):249-258. PMID: 27798808.
30: Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):85-98. PMID: 27366939.
31: Lawson R, Ryan J, King F, Goh JW, Tichy E, Marsh K. Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK. Pharmacoeconomics. 2017 Feb;35(2):225-235. PMID: 27663572.
32: Le P, Rothberg MB. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis. J Gen Intern Med. 2017 Feb;32(2):159-167. PMID: 27743284.
33: Leal J, et al. Cost-Effectiveness of Orthogeriatric and Fracture Liaison Service Models of Care for Hip Fracture Patients: A Population-Based Study. J Bone Miner Res. 2017 Feb;32(2):203-211.PMID: 27632945.
34: Leidner AJ, Chesson HW, Spradling PR, Holmberg SD. Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Appl Health Econ Health Policy. 2017 Feb;15(1):65-74. PMID: 27480538.
35: McLean TR. Interval Appendectomy: Cost-Effectiveness. J Am Coll Surg. 2017 Feb;224(2):219. PMID: 28129836.
36: Moradi-Lakeh M, Yaghoubi M, Hajebi A, Malakouti SK, Vasfi MG. Cost-effectiveness of aftercare services for people with severe mental disorders: an analysis parallel to a randomised controlled clinical trial in Iran. Health Soc Care Community. 2017 Feb 1. PMID: 28147433.
37: Mori T, Crandall CJ, Ganz DA. Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA. Osteoporos Int. 2017 Feb;28(2):585-595. PMID: 27726000.
38: Muralidhar V, Nguyen PL. Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies. Urol Oncol. 2017Feb;35(2):76-85. PMID:27473636.
39: Neidell M, Lamster IB, Shearer B. Cost-effectiveness of diabetes screening initiated through a dental visit. Community Dent Oral Epidemiol. 2017 Feb 1. PMID: 28145564.
40: Osterberg EC, Murphy G, Harris CR, Breyer BN. Cost-effective Strategies for the Management and Treatment of Urethral Stricture Disease. Urol Clin North Am. 2017 Feb;44(1):11-17. PMID:27908365.
41: Panman C, Wiegersma M, Kollen BJ, Berger MY, Lisman-Van Leeuwen Y, Vermeulen
KM, Dekker JH. Two-year effects and cost-effectiveness of pelvic floor muscle training in mild pelvic organ prolapse: a randomised controlled trial in primary care. BJOG. 2017 Feb;124(3):511-520. PMID: 26996291.
42: Pedersen K, Sørbye SW, Kristiansen IS, Burger EA. Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis. BJOG. 2017 Feb;124(3):474-484. PMID: 27264207.
43: Permsuwan U, Dilokthornsakul P, Thavorn K, Saokaew S, Chaiyakunapruk N. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand. J Med Econ. 2017 Feb;20(2):171-181. PMID: 27645706.
44: Qu XM, Louie AV, Ashman J, Wasif N. Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma. Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):339-346. PMID: 28068242.
45: Ristau BT, Geynisman DM. Patient-reported and Cost-effectiveness Outcomes Are
Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell Carcinoma. Eur Urol. 2017 Feb;71(2):210-212. PMID: 27638095.
46: Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017 Feb;32(1):141-145. PMID: 27452949.
47: Shafie AA, Ng CH, Tan YP, Chaiyakunapruk N. Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. Pharmacoeconomics. 2017 Feb;35(2):141-162. PMID: 27752998.
48: Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, Liu S, Shi L. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Curr Med Res Opin. 2017 Feb;33(2):359-369. PMID: 27817216.
49: Shireman TI, et al. Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke: Results From the SWIFT-PRIME Trial (Solitaire With the Intention for
Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke). Stroke. 2017 Feb;48(2):379-387. PMID:28028150.
50: Smith SR, et al. Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis. Arthritis Care Res (Hoboken). 2017 Feb;69(2):234-242. PMID: 27111538.
51: Swart E, Laratta J, Slobogean G, Mehta S. Operative Treatment of Rib Fractures in Flail Chest Injuries: A Meta-analysis and Cost-Effectiveness Analysis. J Orthop Trauma. 2017 Feb;31(2):64-70. PMID: 27984449.
52: Vidal J, Slof J, Serrano D, Marqués T, Kumru H, Benito-Penalva J. Cost-effectiveness of Intrathecal Baclofen Therapy in severe refractory non-focal disabling spasticity: a Spanish hospital perspective. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):67-76. PMID: 27142176.
53: Vodicka EL, et al. Costs of integrating cervical cancer screening at an HIV clinic in Kenya. Int J Gynaecol Obstet. 2017 Feb;136(2):220-228.
54: Wang J, Chmielowski B, Pellissier J, Xu R, Stevinson K, Liu FX. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States. J Manag Care Spec Pharm. 2017 Feb;23(2):184-194. PMID: 28125365.
55: Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD,Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017 Feb;118(2):220-225. PMID: 27923549.
56: Yanagi Y, Fukuda A, Barzey V, Adachi K. Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan. J Med Econ. 2017 Feb;20(2):204-212. PMID: 27701921.
57: Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporos Int. 2017 Feb;28(2):643-652. PMID: 27743068.
58: Zhong Y, Cohen JT, Goates S, Luo M, Nelson J, Neumann PJ. The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients. Appl Health Econ Health Policy. 2017 Feb;15(1):75-83. PMID: 27492419.